Altered Mucins (MUC) trafficking in benign and malignant conditions. by Joshi, Suhasini et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Biochemistry & Molecular 
Biology Biochemistry & Molecular Biology 
2014 
Altered Mucins (MUC) trafficking in benign and malignant 
conditions. 
Suhasini Joshi 
University of Nebraska Medical Center, suhasini.joshi@unmc.edu 
Sushil Kumar 
University of Nebraska Medical Center, skumar@unmc.edu 
Amit Choudhury 
Momenta Pharmaceuticals, Inc. 
Moorthy P. Ponnusamy 
University of Nebraska Medical Center, mpalanim@unmc.edu 
Surinder K. Batra 
University of Nebraska Medical Center, sbatra@unmc.edu 
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles 
 Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons 
Recommended Citation 
Joshi, Suhasini; Kumar, Sushil; Choudhury, Amit; Ponnusamy, Moorthy P.; and Batra, Surinder K., "Altered 
Mucins (MUC) trafficking in benign and malignant conditions." (2014). Journal Articles: Biochemistry & 
Molecular Biology. 49. 
https://digitalcommons.unmc.edu/com_bio_articles/49 
This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at 
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology 
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact 
digitalcommons@unmc.edu. 
Oncotarget7272www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 17
Conditions
Suhasini Joshi1, Sushil Kumar1, Amit Choudhury2, Moorthy P. Ponnusamy1, 
1,3
1
 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, U.S.A;
2
 Momenta Pharmaceuticals, Inc. Cambridge, MA 02142, USA;
3
  Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska 
Medical Center, Omaha, NE 68198, U.S.A.
Correspondence to: 
Dr. Surinder K. Batra, e-mail: sbatra@unmc.edu
Keywords: 
Received: Accepted: Published: 
Abbreviations: TGN, ECD, TM, CT, NLS, 
HSP, HRG, Nup62, EGFR, FGF1, 
Y, AP-2, 
ABSTRACT
Mucins are high molecular weight O-glycoproteins that are predominantly 
expressed at the apical surface of epithelial cells and have wide range of functions. 
The functional diversity is attributed to their structure that comprises of a peptide 
chain with unique domains and multiple carbohydrate moieties added during 
thereby promote proliferation, differentiation, motility, invasion and metastasis. 
Along with their aberrant expression, accumulating evidence suggest the critical 
role of altered subcellular localization of mucins under pathological conditions due 
to altered endocytic processes. The mislocalization of mucins and their interactions 
to proliferate, survive and progress to more aggressive phenotype. In this review 
importance to pathological conditions and to answer critical questions including its 
use for therapeutic interventions.
INTRODUCTION
Mucins (MUC) are high molecular weight 
O-glycoproteins, predominantly expressed at the apical 
expressions of MUC have essential functions to provide 
protection, lubrication to epithelial cells, maintenance of 
epithelial characteristics, cellular adhesion, differentiation, 
altered during tumorigenesis and other pathological 
conditions. For example, MUC4 is not expressed in the 
normal pancreas, but the early pancreatic intraepithelial 
neoplasia (PanINs) precursor lesions have been shown 
to express MUC4, which further increases as the disease 
progresses [4-6]. In addition, MUC4 is also overexpressed in 
breast, gastric and ovarian cancer [7-9], and its overexpression 
has been associated with the poor prognosis of pancreatic 
cancer and cholangiocarcinoma [10, 11]. However, MUC4 
expression is down-regulated during prostate carcinomas 
[12] and urothelial cancer [13], suggesting the complicated 
context-dependent role of mucins. Another example, MUC1 
conditions [1, 14-16]. Besides the aberrant overexpression 
of MUC, emerging evidence suggests that anomalies in 
their subcellular localization and resultant changes in their 
conditions [17].
In a cell, majority of proteins are not pre-set to any 
single location and are in a steady-state distribution due to 
opposing egress (exocytosis) and entrance (endocytosis) 
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pathways [18]. These two pathways are extremely dynamic 
different subcellular compartments. Endocytic pathways 
have always been considered as enduring mechanisms 
for recycling molecules from the plasma membrane 
to different intracellular compartments, and reduce 
receptor density at the cell surface resulting in signal 
attenuation. Proteins could be endocytosed by utilizing 
clathrin-mediated pathway, caveolae-mediated pathway, 
macropinocytosis, and phagocytosis [19]. The MUC1 
utilizes these pathways for endocytosis and cell surface 
localization [20-22] (Fig. 1
MUC are also sorted after their internalization in the 
early or sorting endosome, where their fates are decided 
including their recycling, transportation to the Golgi 
(retrograde), and proteosomal or lysosomal degradation. 
cellular metabolism and signal transduction, but is 
also required for coordinating the functions of each 
and other glycoproteins is mainly regulated by post-
glycosylation, palmitoylation and ubiquitylation.
In this review article, we provide a perspective 
conditions and discuss critical issues surrounding its 
potential use for therapeutic interventions.
MUC BIOSYNTHESIS AND MECHANISM 
OF THEIR SECRETION
membrane bound mucins and secretory mucins. 
Membrane bound mucins (such as MUC1, MUC3, 
MUC4, MUC16, MUC17) have the ability to tether 
themselves into the plasma membrane due to the presence 
of transmembrane domain, whereas secretory mucins 
into secretory vesicles and released upon receiving 
appropriate extracellular signal (Fig. 1) [4]. MUC have 
different physicochemical properties due to the presence 
a single polypeptides chain and are processed into rough 
endoplasmic reticulum and Golgi complex to acquire 
Apart from glycosylation, some MUC are cleaved at 
processing, which create two subunits that remain 
associated throughout their transport from endoplasmic 
MUC, including MUC1, MUC3, MUC16, and MUC17 
ionic concentrations and mechanical stress [4,23,24]. 
to rapidly clear cell surface associated materials or 
colonized/associated pathogens [25,26]. MUC that do not 
sequence [27-29]. The substitution of the aspartic residue 
to the lengthening of the side chain by one carbon, has 
shown to abolish the cleavage [29]. Acidic environment 
of endoplasmic reticulum plays an important role in 
pH for the cleavage. For example, MUC2 cleavage is 
stimulated at pH less than 6 [27], whereas MUC5AC 
cleavage has been demonstrated to occur at neutral pH of 
endoplasmic reticulum [29]. Nevertheless, the cleavage of 
the MUC5AC mucin is augmented at lower pH.
similar for both secretory and membrane bound MUC, 
to variability in their domains. For instance, dimerization 
of MUC2 occurs in the endoplasmic reticulum due 
domain [30] and the subsequent trimerization occur by 
[31]. MUC2 and possibly other gel forming secretory 
epithelia from various harsh conditions. The dense 
formation of large aggregates under high Ca2+ and low pH 
conditions (Fig. 1) [32]. Calcium depletion and HCO3-
mediated pH neutralization can unfold these aggregates 
and tightly clumped MUC. The HCO3- ion transportation 
across the plasma membrane occurred by cystic 
is accompanied with persistently acidic intracellular 
pH. It leads to 3–4 fold increase in the secretion of 
MUC are favored under such acidic condition [33]. 
Three proteins associated with the secretory MUC 
calcium-activated chloride channel 3, and cysteine string 
are considered to be highly crucial as their inhibition 
2+ sensor proteins, are also 
involved in more than 90% of acute MUC secretion upon 
extracellular signals [35].
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ALTERED LOCALIZATION OF MUC
Cytoplasmic localization and its association 
with disease
In 1992, Ceriani and colleagues conducted immuno-
histochemistry (IHC) analysis of MUC1 cytoplasmic and 
membranous expression/localization on 227 breast cancer 
patients. They found that low cytoplasmic intensity and 
high cell surface localization of MUC1 correlated with 
better prognosis of breast cancer patients and survival 
et al., 
who found that increased cell surface MUC1 expression 
have better prognosis, whereas MUC1 cytoplasmic 
localization in tumors correlated with worse prognosis [37]. 
Aberrant cytoplasmic MUC1 localization has also been 
In breast ductal adenocarcinomas, MUC2 and MUC5AC 
are localized in cytoplasm with granular staining pattern 
[14, 39, 40], whereas distribution of MUC5B expression 
changes from apical localization in non-malignant breast 
cells to cytoplasmic and non-apical localization in malignant 
expression has been correlated with poor prognosis, higher 
These studies clearly demonstrate that, aberrant localization 
of MUC is associated with cancer pathology [14, 36, 38, 39], 
Figure 1: Diagrammatical representation of the intracellular transport of glycoproteins along endocytic and exocytic 
pathways. Internalization of cell surface glycoproteins occurs by clathrin-mediated, caveolin-mediated, or clathrin- & caveolin-
independent pathways, followed by the fusion of internalized vesicles with early endosomes where the cargo is sorted and targeted for 
either recycling (from trans-Golgi, late endosome and recycling endosome) or for degradation (in lysosomes). The other exocytic route 
secreted by the exocytic machinery.
Abbreviations: 
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and therefore, it is essential to investigate the mechanisms 
established to understand the elevated intracellular presence 
for MUC1, have been put forth including; its impaired 
recycling, altered glycosylation, altered endocytosis and 
other presumed changes in MUC dynamics (Fig. 2), which 
will be discussed in detail in the next sections.
Nuclear translocation of MUC1
MUC1 in human breast carcinomas but not in normal 
mammary ductal epithelium (Fig. 2A). The cytoplasmic 
domain of MUC1 (or MUC1-C) is comprised of 58 
domain and 72 amino acids of the cytoplasmic tail (CT). 
MUC1-C does not contain a prototypical monopartite 
in MUC16-CT, but it is yet to be investigated for its 
role in MUC 16-CT nuclear translocation [44]. In breast 
cancer cell lines, FGF1 has been found to facilitate the 
targeting of MUC1-C to the nucleus [45]. FGF1 induced 
the phosphorylation of MUC1 on Tyr46 residue, which 
Figure 2: Mechanisms of intracellular transport and sorting of MUC1. MUC1 has demonstrated to be internalization by using 
(A)
(B) and lysosomal (C) translocation resulting 
(D)
roles in deciding the fate of MUC1.
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and thus participates in MUC1-C translocation to the 
of CQC sequence of MUC1-C has been shown to be 
obligatory for MUC1-C nuclear translocation. The 
translocation of the oligomerized MUC1-C into the 
and nucleoporin 62 [46], present on both the cytoplasmic 
and nucleoplasmic sides of nuclear pore complex, 
respectively. However, a recent report has indicated 
that the ectodomain of MUC1 can also translocate to 
the nucleus, although to different area of the nucleus. 
MUC1-C localization to the nuclear periphery, nucleolar 
and in nuclear matrix [47], whereas, the ectodomain of 
area which is primarily associated with the complex and 
crucial process of splicing [48]. Intriguingly, MUC1 
post-transcriptionally stabilizes galectin-3 expression in 
breast cancer cells [49], which was attributed to MUC1 
also be involved, as suggested by the presence of 
it evident for us to reconnoiter whether galectin-3 
expression is regulated by the MUC1-N mediated 
splicing process or not.
Altogether, growth factors induced nuclear 
translocation of MUC1 in conjunction with other 
provides survival and proliferative advantages to the 
cancer cells by inducing the transcription of other proteins 
member-dependent transcriptional upregulation [50].
Mitochondrial translocation of MUC1
localization signal, MUC1-C gets localized to the outer 
membrane of mitochondria by its interaction with cytosolic 
Fig. 
2B). MUC1-C mitochondrial localization has been 
correlated with the diminished cell death response to 
the release of cell-death causing factors. Cytosolic 
sequestration of MUC1 exposes its hydrophobic TM 
domains that facilitate their binding with chaperones, and 
thus targeting to the mitochondria. Interestingly, Heregulin 
HCT116/MUC1 cells [52] and facilitates the translocation 
of MUC1-C to the mitochondria. In breast cancer cells, 
FGF1 plays similar role in the mitochondrial localization 
together, MUC1 translocation to the mitochondria might 
be negatively regulating the programmed cell death.
Lysosomal translocation of MUC1
another subcellular compartment where MUC1-C can 
as used for mitochondrial localization (Fig. 2C) [53]. 
Ca2+ levels and lysosomal permeability, causing death 
of pancreatic cancer cells [54]. However, the exact 
et al. have shown 
physically interaction with MUC1-C. This association 
is followed by the lysosomal translocation of MUC1-C 
[53], which inhibits the release of lysosomal hydrolytic 
cathepsin L. These cathepsins can functions even at 
a neutral cytosolic pH and have the ability to activate 
apoptotic effectors such as calpains and caspases to 
elicit apoptotic processes [55]. However, MUC1  over-
expression followed by its cleavage to generate MUC1-C 
is very well utilized by cancer cells to protect them from 
harsh apoptotic programs.
Hence, altered localization of MUC1-C to the 
lysosome followed by its interaction with overexpressed 
cathepsins mediated cell death response by inhibiting their 
release from lysosome.
POST TRANSLATIONAL 
MODIFICATION AND THE ABERRANT 
LOCALIZATION OF MUC
Glycosylation
tyrosine and serine residues and serve as sites for extensive 
of their molecular weight and imparts most of their antigenic 
epitopes [56]. Inhibition of O-glycosylation by 1-benzyl-2-
impedes the apical targeting of glycoproteins by inhibiting 
membrane, as this inhibitor interferes with the localization 
XIIIb [57]. Besides O-glycosylation, MUC also contain 
potential N-glycosylation sites. For example; MUC13 
have seven N-glycosylation sites [58]. N-glycosylation of 
MUC plays important roles in their folding, sorting, and 
which results in the accumulation of glycoproteins in the 
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[60]. However, due to unresolved issues including that of 
targeting.
It has been observed that epithelial cancers expresses 
MUC1 with truncated or under-glycosylated glycans, 
antigens [21]. Comparison of the stability of the 
differentially glycosylated forms of MUC1, derived from 
plasma membrane to the degradation pathway. In a parallel 
experiment, addition of exogenous GalNAc to the culture 
media resulted in MUC1 stabilization on the cell surface 
(60% of fully glycosylated MUC1), emphasizing the 
importance of glycosylation in MUC stability. On the other 
hand, MUC1 with short glycan structures have shown two-
fold higher rate of endocytosis via the hypertonic-media 
sensitive clathrin-mediated pathway, along with increased 
intracellular sequestration, as compared to the mature [35
MUC1 [20, 21]. Interestingly, this increased internalization 
of truncated MUC1 was not followed by its degradation. 
Apart from clathrin-mediated endocytosis, a separate 
study has shown that MUC1 can also be endocytosed 
via macropinocytosis (Fig. 1) [22], which suggests the 
involvement of multiple endocytic pathways in MUC1 
internalization. These observations raise questions, such 
responsible for increased MUC1 endocytosis and does 
the mode of internalization for MUC1 change during 
pathological condition? Answer to these questions can 
help us to design better strategies against MUC1 targeted 
antigens.
et al have suggested that membrane-
localized and secretory MUC1, both have altered O-glycan 
core structures, due to the differential pathway of their 
tagged MUC1 (MUC1-M), mutants with defective 
clathrin-mediated endocytosis (MUC1-M-Y20,60N) and 
mutants with recycling defects (palmitoylation-defective 
MUC1-M-CQC/AQA). Intriguingly, CQC/AQA mutants 
and accumulation in endosomal compartments. Analysis 
of shed MUC1 ectodomain subunit of the CAC/AQA 
mutant revealed change in the core glycan structures from 
sialylated core 1 (MUC1-M, wild-type) to core 2 glycans 
on the non-recycling CQC/AQA mutant. Interestingly, the 
MUC1 which enters only once to the Golgi complex [61]. 
60N mutant resembles the wild-type phenotype with 
dominant core 1 expression.
Sialylation
of MUC also differed in cancer cells as compared to the 
normal healthy cells. Previous reports have demonstrated 
the presence of immature form of episialin (MUC1) on 
the cell surface under cancerous conditions. The immature 
episialin is convertible to mature form by addition of sialic 
residues through consecutive internalization and routing 
of the MUC1 to the TGN (Fig. 2D) [62]. The half-life 
of MUC1 at the plasma membrane has been calculated 
around 2.5 hours [62], which suggests that MUC1 
possibly undergo recycling about 9–10 times. The multiple 
rounds through TGN generate abnormally high levels of 
sialylation [62], and have been correlated with increased 
with the poor prognosis of colon cancer patients [68]. In 
ligands, the unusual higher levels of sialylation of MUC 
could play a critical role in the invasion and metastasis 
Palmitoylation
can be palmitoylated. This motif in MUC1 is present at 
the boundary of TM domain and cytoplasmic tail, and its 
palmitoylation has been correlated with MUC1 plasma 
membrane retention. This MUC1 retention is achieved by 
regulating MUC1 recycling at the apical surface without 
interfering or altering the rate of its endocytosis [17]. 
residues at position 20 and 60 in the MUC1-CT domain, 
in the process of endocytosis [70]. The Y20N mutation in 
of MUC1 with the adaptor proteins AP-1 and AP-2, 
whereas the Y60N mutation inhibits MUC1 association 
with another adaptor protein called Grb2. Transfection of 
CHO cells with double mutant; AQA mutant and Y20N 
of the mutant for AP-1, and thus poor recycling. On the 
other hand, transfection of Y20N mutant showed reduction 
in the rate of endocytosis and internalization, however, 
the subcellular distribution of MUC1 remain unchanged. 
an important role in MUC1 routing from endosomes to the 
plasma membrane. Palmitoylation of MUC1 cytoplasmic 
tail might be inducing conformational changes which 
could interfere with the interactions between MUC1-
CT and endocytosis regulating proteins. It is noteworthy 
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signaling proteins [71]. The precise mechanism by which 
clear. The palmitoylation and depalmitoylation status permit 
clinical perspective, it may be worthwhile to design targeted 
therapies against palmitoylation regulating enzymes.
DIFFERENTIAL INTERACTION OF 
MUCINS WITH PROTEINS UNDER 
PATHOLOGICAL CONDITION
Additional factors may also modulate the 
localization of MUC under cancerous conditions. One 
example is the differential MUC interactions due to 
galectin-3 overexpression (Fig. 1) [73]. Galectin-3 
is predominantly expressed as a cytosolic protein in 
epithelial tissues, though it can also localize to the 
nucleus, mitochondria and extracellular regions [74]. In 
pancreatic cancer, silencing of galectin-3 has shown to 
enhance the cell surface interaction between MUC1 and 
leads to the noticeable cell surface localization of MUC1. 
However, presence of EGF stimulation leads to the nuclear 
surface and MUC1-CT nuclear localization [75]. Upon 
discernible redistribution of MUC1 from the cell surface 
to the cytoplasm was observed [75]. Therefore, galectin-3 
overexpression in cancer could possibly be related to the 
frequently observed intracellular retention of MUC1.
MODULATION OF SUB-CELLULAR 
PROTEIN TRAFFICKING BY MUCINS
and MUC4) localize all over the cell surface, instead 
allows them to interact with cell surface proteins such 
the basolateral sides of polarized cells [76, 77]. MUC4 
pancreatic cancers [76, 78]. MUC4-ErbB2 complex lead 
to the activation of various signaling pathways leading 
to cell proliferation and survival through stimulation 
the soluble ligand, the MUC4-ErbB2 complex leads 
to ErbB2 phosphorylation, which in turn, leads to the 
phosphorylation of the ErbB2-ErbB3 heterodimer in the 
presence of neuregulin [80]. MUC4 did not demonstrate 
interaction with ErbB3 in polarized cells, but loss of 
polarity facilitates MUC4-ErbB3 interaction.
The tradeoff between phosphorylation and 
polarized breast epithelia which resulted in increased 
motifs located at the juxtamembrane domains [82]. The 
which has been implicated in the pathogenesis of colonic 
intracellular MUC1-CT to regulate MUC1 mediated 
cellular proliferation [83]. The MUC1-CT and E-cadherin 
cellular polarity [45, 84].
at the lateral side of the cell. The loss of polarity allows 
present in MUC1-C and the loss of E-cadherin-mediated 
cell-to-cell interaction at MUC1 positive sites. Under 
XXXXX
the maintenance of the adherent junction. This interaction 
mediated phosphorylation of the crucial tyrosine residues 
present on MUC1-CT [47]. Additionally, phosphorylation 
binding motif inhibits the interaction between MUC1 and 
Armadillo repeats and the non-repetitive COOH-terminal 
and translocate to the nucleus to transcriptionally activate 
various genes implicated in increased carcinogenic 
potential and metastasis [88]. In breast and colon cancers, 
present in MUC16-CT [89]. However, MUC16 secretion 
cancer cell lines caused increased cytoplasmic localization 
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cellular motility and invasiveness [89]. In agreement, 
reduction of MUC16 expression has been related with 
studies pointed towards the possibility that the interactions 
MUC16 to modulate various signaling pathways.
Bitler et al. found evidence that MUC1 has 
machinery at the promoter region, as the loss of MUC1 
 
region [47]. Besides controlling such inter-molecular 
which is an early endosome protein belonging to the 
and are responsible for the transcriptional activation 
treatment indicating the possible involvement of these 
therapy [92].
THERAPEUTIC PERSPECTIVES
The altered MUC localization and interactome 
under pathological conditions provide new avenue 
for the therapeutic intervention. Multiple studies have 
investigated the potential of two well characterized MUCs, 
MUC1 and MUC4, as therapeutic targets by restraining 
their subcellular localization.
MUC1-C inhibitors
exploited to enhance anti-cancer drug sensitivity of 
melanoma cells. Melanoma cells showed 10-fold increase 
cis-platin), carboplatin and other anti-cancer drugs upon 
depletion of the vacuolar protein sorting 33A or the 
cappuccino protein [93], which strongly signpost the idea 
can increase the drug sensitivity of cancer cells.
GO-201 and GO-202 are two small peptides 
that recognize the CQC motif in the amino terminal of 
MUC1-C responsible for the translocation of MUC1-C 
to various sub-cellular organelles [94]. Both GO-201 
and GO-202 showed anti-tumorigenic functions in vitro 
and in xenograft models [94]. Targeting the endocytic 
be accomplished by modulating the expression of critical 
to participates in MUC1 internalization [22], and as 
modulated under different disease conditions, such as 
carcinomas [95, 96], and induce the invasive ability of 
to reroute MUC to the degradation pathways. Other 
which as a consequence, obstructed MUC1 targeting to the 
mitochondria [45].
MUC4 effects on HER2 internalization
by inhibiting its internalization in pancreatic cancer 
[76], whereas MUC1 induces the internalization of 
upregulation of oncogenic factors [47]. Presence 
of MUC4 and MUC1-C has also been related with 
Herceptin resistance in breast cancer [99, 100]. One of the 
mechanism by which Herceptin functions is by binding 
internalization for lysosomal mediated degradation [101]. 
designing peptides against their interacting motifs could 
has shown that administration of GO-203 downregulates 
the levels of phospho-p27 and cyclin-E, which abrogates 
Herceptin resistance in breast cancer [102]. As MUC4 
is one of the most differentially expressed proteins in 
pancreatic cancer and has been associated with the 
trial in pancreatic cancer could possibly be attributed to 
MUC4 aberrant overexpression, which requires further 
investigation.
SUMMARY AND CONCLUSIONS
MUCs are the major macromolecular components 
of epithelial mucus and have been incriminated in the 
pathogenesis of various diseases. Their mislocalization 
has been well associated with the pathobiology of several 
cancers such as, breast and colorectal cancer. Under 
normal condition, MUC are localized predominantly 
on the apical surface, but loss of polarity allows them 
to extend all over the cell surface and modulate their 
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play crucial role in determining these interactions. 
Mislocalization of MUC also facilitates MUC interactions 
to different subcellular compartments. Though many 
conjectures, including altered glycosylation, sialylation, 
and differential protein-protein interactions, have been 
made to answer altered localization of MUC, the exact 
mechanism has not been explored and need immediate 
attention for therapeutic interventions.
FUTURE DIRECTIONS
membrane targeting can also be modulated by regulating 
MUC can be directed to the degradation pathways, 
rather than to the cell surface. This strategy has been 
clinically utilized to generate a number of peptide-
based inhibitors [94]. A recent report indicated that a 
elicit strong humoral and cellular immune responses 
[103]. Technological advancements, particularly in mass 
spectrometry, have enabled the characterization of the 
entire structure of O-glycans. It would be interesting to 
determine the structural differences between O-glycans 
and N-glycans in MUC expressed under normal and 
pathological conditions and to correlate them with changes 
will not only give us deeper insight into MUC biology, 
but will also help us design novel therapeutic strategies 
to treat cancers. In addition, structural differences arise 
as a result of altered glycans could be responsible for 
the altered mucin interaction with other proteins such as 
localization.
Besides these alteration, other standing questions 
following the classical pathway dependent on importins 
and nucleoporins; does it go through a non-classical 
CQC motif of MUC1-C regulated? Under what stimuli, the 
fate of the subcellular targeting of MUC1-C is determined? 
What functions MUC1-N have in the nucleus? Is there 
any correlation between altered splicing and MUC1 
overexpression in cancer? How is MUC1-N translocation 
to the nucleus regulated and/or mediated? The outcome 
of CQC palmitoylation or its nuclear/ mitochondrial/
lysosomal translocation may be very different depending 
Nuclear localization of MUC16 has also been speculated 
MUC16-CT, which needs to be validated due to its well-
established oncogenic role in multiple cancers.
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